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A stability study of azithromycin in ophthalmic preparations was developed by submission to different 
types of light, temperature and pH, using the biodiffusion assay (cylinder 3 x 3) for the quantifications. 
Bacillus subtilis, ATCC 9372, was used as test organism. The used concentration range was of 50 to 
200 µg/mL. The study demonstrated that the drug suffered degradation when submitted to the ultraviolet 
light, germicide light, solar luminosity, acid solution, basic solution and hydrogen peroxide solution. 
The results were analyzed by the analysis of variance (ANOVA).
Uniterms: Azithromycin/stability study. Bioassay. Photodegradation. Ophthalmic preparations.
O estudo de estabilidade de azitromicina em preparações oftálmicas foi realizado após exposição a 
diferentes tipos de luz, temperatura e pH, utilizando o método de difusão em ágar (cilindros 3 x 3) para 
as quantificações. A faixa de concentração foi de 50 a 200 mg/mL. O estudo demonstrou que o fármaco 
sofreu degradação quando submetido às luzes ultravioleta, germicida e solar, e a soluções ácida, alcalina 
e de peróxido de hidrogênio. Os resultados foram analisados através da análise da variância (ANOVA).
Unitermos: Azitromicina/estudo de estabilidade. Bioensaio. Fotodegradação. Preparações oftálmicas.
INTRODUCTION
Stability is defined as the capacity of a drug substan-
ce or drug product to remain within established specifica-
tions to maintain its identity, strength, quality, and purity 
throughout the retest or expiration dating periods (Brasil, 
2005; Nudelman, 1975; Yoshida, Sato, Moroi, 1993). 
Due to their possible composition, pharmaceuticals are 
especially sensitive to environmental factors. Strict storage 
conditions are necessary for the maintenance of integrity 
and product activity (Waterman, Adami, 2005). 
Stability test of an active substance or finished pro-
duct provides evidence on the drug quality and its variation 
with the time, influenced by a variety of environmental 
factors such as temperature, humidity and light (Tonnesen, 
2001). The Brazilian stability studies guidelines were pu-
blished at the document RE nº 1, on July 1st, 2005, which 
determined the specifications for this specific analysis 
(Brasil, 2005).
The azithromycin (Figure 1), is 1-oxa-6-azacyclo-
pentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O 
-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10- 
trihydroxy-3,5,6,8,0,12,14-heptamethyl-11-[3,4,6-trideo-
xy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy], 
dihydrate, is an azalide, a subclass of macrolide antibiotics. 
The macrocyclical lactone expansion and the presence of 
nitrogen atom in the lactone ring are responsible for the 
best pharmacological and microbiological azithromycin 
characteristics. Azithromycin has similar antimicrobial 
spectrum as erythromycin, but is more effective against 
certain gram-negative bacteria, particularly Haemophilus 
influenzae.
Azithromycin prevents bacteria from growing by 
interfering with their protein synthesis. Azithromycin bin-
ds to the 50 S subunit of the bacterial ribosome, and thus 
inhibits translation of mRNA. Nucleic acid synthesis is not 
affected (Korolkovas, 2000; United States Pharmacopeia, 
2005; Zanini et al., 1998).
Azithromycin is commercialized by Brazilian 
pharmacies as ophthalmic solution, with concentration of 
1.667 mg/mL in physiological buffered vehicle (Zanini 
et al., 1998).
For many aqueous drug solutions, stress conditions 
such as pH, temperature, light and oxidizing atmosphere 
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can sometimes affect the maximum stability of the drug 
(Kommanaboyina, Rhodes, 1999). For this reason, the aim 
of the study was to evaluate the stability of azithromycin 
in ophthalmic solutions face to several stress conditions, 
such as temperature, light and acid, alkaline and hydrogen 
peroxide solutions.
MATERIAL AND METHODS
 Material
Azithromycin reference substance was gently 
supplied by the Ariston Laboratory (São Paulo, Brazil). 
Azithromycin raw material and ophthalmic solutions were 
gently supplied by the Bandeirantes Pharmacy (Arara-
quara, Brazil). Azithromycin ophthalmic solutions were 
claimed to contain 1.667 mg/mL (as anhydrous base) of 
the drug. All used chemicals were of analytical grade.
Preparation of azithromycin reference substance
The standard and sample stock solutions were prepa-
red by dissolution in water (100 mg in a 50 mL volumetric 
flask) and then diluted with potassium phosphate buffer 
solution pH 8.0 and sonicated by 10 min (2000 mg/mL). 
Standard solutions were freshly prepared in the concen-
trations of 50.0, 100.0 and 200.0 µg/mL by transferring 
aliquots of 250.0, 500.0 and 1000 mL, respectively, of the 
stock solution to 10 mL volumetric flasks and diluting to 
volume with potassium phosphate buffer solution pH 8.0.
Potassium phosphate buffer solution
Amounts of 16.73 g of dipotassium hydrogen phos-
phate and 0.52 g of potassium dihydrogen phosphate were 
dissolved in 1000 mL of distilled water (pH = 8.0).
Preparation of the azithromycin solutions 
A commercial ophthalmic solution composed by 
azithromycin 25.0 mg in 15.0 mL of physiological solution 
with concentration of 1.667 mg/mL was used to prepare 
the sample solutions: 3.0 mL, 6.0 mL, and 12.0 mL of azi-
thromycin commercial ophthalmic solution (10 samples) 
were transferred to a 100 mL volumetric flask and dilu-
ted to volume with potassium phosphate buffer solution 
pH 8.0, to give final concentrations of 50.0, 100.0 and 
200.0 µg/mL, respectively.
Organism and inoculum 
The quantitative measurement of the azithromycin 
was carried out through diffusion in a test-agar using 
Bacillus subtilis ATCC 9372 as indicator microorganism. 
The cultures of B. subtilis ATCC 9372 were stored on 
Grove-Randall number 1 agar (Merck, Brazil) at freezer 
and pealed to another Grove Randall number 1 agar (24 h 
before assay) that was kept at 37ºC. The bacteria were sus-
pended in brain heart infusion broth (Merck, Brazil) using 
a glass homogenizer. Diluted culture suspensions of 25% ± 
2% turbidity were obtained at 580 nm (Farmacopéia Bra-
sileira, 1988), using a suitable spectrophotometer (Merck 
SQ118, Germany) and a 10 mm diameter test tube as an 
absorption cell against brain heart infusion broth as blank.
Biodiffusion assay
The agar was composed of 2 separate layers, and 
only the upper layer was inoculated. The Grove-Randall 
number 11 agar (20 mL) was poured into microbiological 
petri dish (100 mm x 20 mm) for the base layer. After so-
lidification, the inoculum (5.0 mL) was distributed to the 
surface of each base layer. Six stainless steel cylinders of 
uniform size (8 mm x 6 mm x 10 mm) were placed on the 
surface of inoculated agar and an exactly measured volume 
(200 mL) of the corresponding dilution was deposited into 
each cylinder. Three alternated cylinders were filled with 
200 mL of reference substance and sample solutions. In this 
way, each dish contained three cylinders with three diffe-
rent azithromycin reference substance dilution and three 
cylinders with the corresponding sample concentrations. 
The bioassay plates were aerobically incubated at 35 ºC ± 
2 ºC for 18 h. The diameter (in mm) of growth inhibition 
zones was carefully measured using a caliper (Mitutoyo, 
Japan) with a precision of at least 0.1 mm. Six plates were 
used in each assay as shown in Figure 2. 
The percentage activity of azithromycin in ophthal-
mic solutions was calculated by Hewitt equations 
FIGURE 1 -  Chemical structure of the azithromycin 
(C36H72N2O12. H2O; Mr 785.02; CAS 83905-01-5).
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(Hewitt, 1977). The assay was statistically calculated 
by linear parallel model and by means of regression 
analysis, being then verified using analysis of variance 
(ANOVA).
Azithromycin degradation tests
Sample solutions (50.0, 100.0 and 200.0 µg/mL) 
prepared for the biodiffusion assay were stored in glass 
bottles closed and submitted the following expositions: 
temperature (50 and 100°C per 20 and 60 days); ultraviolet 
light 284 nm (10 cm from the source for 1, 2, 7, 14, 21 and 
28 days); solar light (for 2, 5, 7 and 10 days); ultraviolet 
germicide light 254 nm (10 cm from the source for 2, 6, 12, 
24, 36, 48 and 72 hours). The lamps used in the test were 
UV Lamp SM808 (Zheijang, China) and UV Germicidal 
Lamp (Zheijiang, China).
Portions of 10 mL of the ophthalmic solutions 
(1.667 mg/mL) were transferred to three flasks in order to 
develop the chemical degradation study with 0.1 mol/L 
hydrochloric acid, 0.1 mol/L sodium hydroxide and 
0.3 % (v/v) hydrogen peroxide solutions:
Acid degradation
5.0 ml of 0.1 mol/L hydrochloric acid solution was 
added to the ophthalmic solution (1.667 mg/mL). The 
solution was warmed in a bath at 70 °C, ± 2 °C, during 
6 hours, cooled and neutralized with 5.0 mL of 0.1 mol/L 
sodium hydroxide solution. Portions of 1.5, 3.0 and 6.0 mL 
were transferred to 25 mL volumetric flasks and diluted to 
volume with purified water to give final concentrations of 
50.0, 100.0 and 200.0 µg/mL, respectively.
Alkaline degradation
5.0 ml of 0.1 mol/L sodium hydroxide solution was 
added to the ophthalmic solution (1.667 mg/mL). The 
solution was warmed in a bath at 70 °C, ± 2 °C, during 
6 hours, cooled and neutralized with 5.0 mL of 0.1 mol/L 
hydrochloric acid solution. Portions of 1.5, 3.0 and 6.0 mL 
were transferred to 25 mL volumetric flasks and diluted to 
volume with purified water to give final concentrations of 
50.0, 100.0 and 200.0 µg/mL, respectively.
Degradation with hydrogen peroxide
5.0 mL of 0.3 % (v/v) hydrogen peroxide solution 
was added to the ophthalmic solution (1.667 mg/mL). 
The solution was warmed in a bath at 70 °C ± 2 °C, 
during 6 hours, cooled and added 5.0 mL of purified 
water. Portions of 1.5, 3.0 and 6.0 mL were transferred to 
25 mL volumetric flasks and diluted to volume with puri-
fied water to give final concentrations of 50.0, 100.0 and 
200.0 µg/mL, respectively.
After the sample expositions, the assays for drug 
quantification were developed by biodiffusion assay (Sal-
gado, Roncari, 2005) and the potency calculated by Hewitt 
equations (Hewitt, 1977). The assay was statistically cal-
culated by linear parallel model and regression analysis 
using analysis of variance (ANOVA) (AOAC, 1990).
RESULTS AND DISCUSSION
Pharmaceutical products quality is of vital impor-
tance for patient safety. The presence of impurities may 
influence the efficacy and safety of pharmaceuticals. 
Impurities and potential degradation products can cause 
changing of chemical, pharmacological and toxicological 
properties of drugs, having significant impact on product 
quality and safety (Tonnesen, 2001). Stability studies of 
pharmaceutical preparations become necessary, to assure 
product purity, safety, potency and effectiveness until use 
(Nudelman, 1975).
Stress studies are said to be useful to determine if 
accidental exposures to conditions other than those propo-
sed have been deleterious to product; in order to evaluate 
which specific test parameters would be the best indicators 
of product stability; and to reveal the degradation pat-
terns. Stress conditions are also mentioned in literature 
on establishment of stability-indicating assays. The total 
information was tabulated for different types of activities, 
such as hydrolysis in acid, alkaline and neutral conditions, 
oxidation and photolysis (ICH, 1996).
According to ICH (1996), the most used stress 
FIGURE 2 - Delineation 3 x 3, demonstrating the standard 
solutions (P) and sample solutions (A) disposed in Petri dishes, 
where P1 (50.0 µg/mL); P2 (100.0 µg/mL); P3 (200.0 µg/mL) and 
A1 (50.0 µg/mL); A2 (100.0 µg/mL); A3 (200.0 µg/mL).
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conditions for decomposition study in acid medium were 
based on hydrochloric acid at strength of 0.1 mol/L. The 
temperature range varied from 40 ºC up to 110 ºC, and 
drugs were kept under temperature conditions for periods 
ranging from few minutes up to 2 months.
The stress conditions used for the hydrolysis of 
drugs under alkaline conditions run in parallel to those 
used for acid conditions. Sodium hydroxide is most used, 
at strength of 0.1 mol/L. Just like acidic degradation, a 
lot of variation is observed respecting time and exposure 
temperature of drugs to alkali.
The hydrogen peroxide seems to be much more 
popular for the purpose than any other oxidizing agents. 
The used strength of hydrogen peroxide varies between 
1% to 30%. In some drugs, extensive degradation is seen 
when exposed to 3% hydrogen peroxide, for very short 
time periods, at room temperature. These conditions are 
not expected to show any change, even in the presence of 
high dose of oxidizing agents. The drug may be declared 
to be “practically stable” if no products are formed on 
subjecting the drug to this condition.
Light exposure can induce chemical degradation 
in susceptible molecules and the most obvious result of 
drug photodecomposition is the product loss of potency 
(Tonnesen, 2001). Mostly, drugs are exposed to short/
long wavelength UV light, or fluorescent light of varying 
illumination. Efforts are usually made to maintain the tem-
perature around room temperature. The period of exposure 
ranges from a few hours to several months, depending on 
the light source intensity. Like oxidation, based on whether 
a drug is photolytic or not, varied types of decomposition 
behaviors are seen. Photolability studies are done on drugs 
in either solid or solution forms (ICH, 1996).
The sample solutions presented loss of the drug 
potency after the stress expositions, according to Table 
I. The ultraviolet light (284 nm) showed considerable 
potency loss (18.86%) after 28 days when compared with 
other exposition types, such as temperature, ultraviolet 
germicide light (254 nm) and solar light. However, the 
chemical degradation by acid, alkali and hydrogen peroxi-
de presented almost total potency loss of the drug (11.5%), 
indicating drug susceptibility for direct degradation. No 
interference from the sample excipients and vehicles could 
be observed under experimental conditions.
The biodiffusion assay can reveal subtle changes 
not demonstrated by chemical methods, such as chemi-
cal degradation, and allows evaluation of azithromycin 
potency (Andrews, 1999; Breier et al., 2002; Turcinov, 
Pepeljnjak, 1998). Figure 3 represents the drug potency 
decline after different types of expositions: temperature 
FIGURE 3 - Azithromycin potency decline after different types of expositions: temperature 50 ºC (A); ultraviolet light (B); solar 
light (C); ultraviolet germicide light (D).
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50ºC (A); ultraviolet light (B); solar light (C); ultraviolet 
germicide light (D).
According to the Figure 3 the loss of potency was 
considerable when the samples were exposed to tempe-
rature (A) and ultraviolet light (B), showing the product 
susceptibility to light and thermal degradation.
The inhibition zones of azithromycin without degra-
dation are represented in Figure 4, and the Figures 5, 6, 
7 and 8 showed the zone diameters for the azithromycin 
under chemical degradation (acid, alkaline and hydrogen 
peroxide solutions), UV light (284 nm), UV germicide 
light (254 nm) and solar light, respectively.
There were clear reduction of zone diameters, spe-
cially for the azithromycin under chemical degradation, 
when compared with the inhibition zone at zero time 
(product not degraded) (Figures 4 and 5). The Figures 6, 
7 and 8 showed the photodegradation of azithromycin. 
According to figures, the UV light (284 nm) exposition 
was more deleterious than UV germicide light (254 nm) 
and solar light expositions. Biological products such as 
antibiotics are particularly sensitive to stress conditions. 
Their main routes of decomposition can also vary, depen-
ding on the used chemical agents.
Segregation and quantification of antibiotic compo-
nents by chemical methods such as HPLC, although pre-
cise, may not provide a true indication of their biological 
activity, and attempts to correlate antibiotic bioassay re-
sults with those from chemical methods have been usually 
disappointing. So, these results demonstrate that bioassays 
continue to play an essential role in the manufacture and 
quality control of antibiotic medicines.
The biodiffusion assay used for the azithromycin 
quantification was validated by Salgado and Roncari 
(2005). The statistical analysis demonstrated the appli-
cability of the method: there were no deviations from 
parallelism and linearity with results obtained (P < 0.05). 
Table I shows the results obtained for azithromycin deter-
minations after the stress expositions.
The stability study has as main goals to explore the 
nature, kinetic course and degradation of drugs, as well 
as determining for how much time products can conserve 
their original constitution (Marona, Zuanazzi, Schapoval, 
1999; Marona, Schapoval, 2001). Quality control in the 
pharmaceutical industry is very important to assure effec-
tiveness and confirm the quality of the medicines being 
commercialized for the population.
CONCLUSIONS
In this study, we concluded that it is necessary to be 
worried about the form, place and storage time of drugs, 
so that degradation reaction could be avoided: pH must 
be controlled, avoiding extreme values, as the chemical 
degradation presented almost total loss of drug potency; 
and light expositions showed considerable loss of drug 
potency as well. These procedures can avoid the drug de-
gradation and the consequent product loss of effectiveness 
and security. These studies are important to establish the 
type and adequate places for storage of pharmaceutical FIGURE 4 - Zone diameters for the azithromycin at zero time.
FIGURE 5 - Zone diameters for the azithromycin under different chemical conditions of degradation studies (acid, alkaline and 
hydrogen peroxide solutions). 
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FIGURE 6 - Zone diameters for the azithromycin under UV light (284 nm) exposition.
FIGURE 7 - Zone diameters for the azithromycin under UV germicide light (254 nm) exposition.
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TABLE I – Experimental values obtained for the determination of azithromycin by the biodiffusion assay after stress expositions
Exposition Period Potency (%) CV (%)
Temperature 50 ºC 20 days 61.17 0.89
Temperature 50 ºC 60 days 59.90 0.73
Temperature 100 ºC 20 days total powder loss -
Ultraviolet light
(284 nm)
1 day 85.39 1.56
2 days 80.85 0.54
7 days 42.88 0.45
14 days 29.57 0.76
21 days 23.49 0.51
28 days 18.86 0.88
Ultraviolet germicide
light (254 nm)
2 hours 96.93 0.61
6 hours 96.87 0.50
12 hours 87.35 1.19
24 hours 78.70 0.63
36 hours 69.43 0.38
48 hours 62.24 1.15
72 hours 60.02 0.89
Solar light 2 days 89.27 0.77
5 days 86.14 0.83
7 days 77.70 0.49
10 days 74.25 0.65
Acid degradation 6 hours total powder loss -
Alkaline degradation 6 hours total powder loss -
Hydrogen peroxide degradation 6 hours 11.50 0.90
FIGURE 8 - Zone diameters for the azithromycin under solar light exposition.
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preparations, in order to prevent the degradation after ex-
positions, assuring the drug integrity, and product quality 
and safety for the user.
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